Study of Urate Elevation in Parkinson's Disease, Phase 3
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine
whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0
mg/dL) over 2 years slows clinical decline in early PD.
Clinical decline will be assessed as change in the primary outcome variable of the Movement
Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a composite scale
comprising patient- and clinician-reported outcomes.
Phase:
Phase 3
Details
Lead Sponsor:
Michael Alan Schwarzschild
Collaborators:
Michael J. Fox Foundation for Parkinson's Research National Institute of Neurological Disorders and Stroke (NINDS) The Parkinson Study Group University of Rochester